Making cytology specimens solid materials for testing predictive marker of immunotherapy in NSCLC.
作者信息
Wang Hangjun, Spatz Alan
机构信息
Division of Pathology, Jewish General Hospital and McGill University Health Center, Montreal, Quebec, Canada.
出版信息
Oncotarget. 2018 Oct 26;9(84):35472-35473. doi: 10.18632/oncotarget.26261.
Abstract
摘要
相似文献
1
Making cytology specimens solid materials for testing predictive marker of immunotherapy in NSCLC.将细胞学标本制成固体材料，用于检测非小细胞肺癌免疫治疗的预测标志物。
Oncotarget. 2018 Oct 26;9(84):35472-35473. doi: 10.18632/oncotarget.26261.
2
PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer.非小细胞肺癌 EBUS-FNA 细胞学标本的 PD-L1 检测。
Lung Cancer. 2019 Oct;136:1-5. doi: 10.1016/j.lungcan.2019.07.033. Epub 2019 Aug 1.
3
PD-L1 immunohistochemical testing: A review with reference to cytology specimens.PD-L1 免疫组织化学检测：细胞学标本的相关综述。
Diagn Cytopathol. 2023 Jan;51(1):51-58. doi: 10.1002/dc.25043. Epub 2022 Aug 20.
4
PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.非小细胞肺癌中程序性死亡受体配体1（PD-L1）的表达：细胞学、小活检及手术切除标本的比较
Cancer Cytopathol. 2017 Dec;125(12):896-907. doi: 10.1002/cncy.21937. Epub 2017 Oct 12.
5
EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.非小细胞肺癌中 PD-L1 免疫组化的 EBUS-FNA 细胞学-组织学相关性。
J Am Soc Cytopathol. 2020 Nov-Dec;9(6):485-493. doi: 10.1016/j.jasc.2020.04.003. Epub 2020 Apr 6.
6
Cytology for PD-L1 testing: A systematic review.PD-L1 检测的细胞学：系统评价。
Lung Cancer. 2020 Mar;141:101-106. doi: 10.1016/j.lungcan.2020.01.010. Epub 2020 Jan 13.
7
Comprehensive assessment of PD-L1 immunohistochemistry on paired tissue and cytology specimens from non-small cell lung cancer.对非小细胞肺癌配对组织和细胞学标本的 PD-L1 免疫组化的全面评估。
Lung Cancer. 2020 Aug;146:276-284. doi: 10.1016/j.lungcan.2020.06.002. Epub 2020 Jun 17.
8
Adequate tumour cellularity is essential for accurate PD-L1 immunohistochemistry assessment on cytology cell-block specimens.足够的肿瘤细胞含量对于细胞学细胞块标本上 PD-L1 免疫组织化学评估的准确性至关重要。
Cytopathology. 2020 Mar;31(2):90-95. doi: 10.1111/cyt.12795. Epub 2020 Jan 11.
9
Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.程序性死亡配体 1 检测在非小细胞肺癌细胞学细胞块和抽吸涂片制备中的应用。
Cancer Cytopathol. 2018 May;126(5):342-352. doi: 10.1002/cncy.21987. Epub 2018 Mar 2.
10
Programmed death-ligand 1 testing of lung cancer cytology specimens obtained with bronchoscopy.经支气管镜获取的肺癌细胞学标本的程序性死亡配体 1 检测。
Cancer Cytopathol. 2018 Feb;126(2):122-128. doi: 10.1002/cncy.21941. Epub 2017 Oct 20.
引用本文的文献
1
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).程序性死亡配体 1（PD-L1）作为预测晚期非小细胞肺癌（NSCLC）患者接受派姆单抗治疗的生物标志物。
Adv Ther. 2019 Oct;36(10):2600-2617. doi: 10.1007/s12325-019-01057-7. Epub 2019 Aug 20.
2
Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients.比较非小细胞肺癌患者配对的细胞学和组织学标本中的 PD-L1 表达。
Virchows Arch. 2020 Feb;476(2):261-271. doi: 10.1007/s00428-019-02632-7. Epub 2019 Aug 7.
本文引用的文献
1
PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?使用克隆22C3免疫组化检测试剂盒进行程序性死亡受体配体1（PD-L1）检测以选择接受免疫检查点抑制剂治疗的非小细胞肺癌患者：细胞学细胞块是一个可行的选择吗？
J Am Soc Cytopathol. 2018 May-Jun;7(3):133-141. doi: 10.1016/j.jasc.2018.02.003. Epub 2018 Feb 16.
2
Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer.细胞学细胞块适合用于肺癌中 PD-L1 的免疫组织化学检测。
Ann Oncol. 2018 Jun 1;29(6):1417-1422. doi: 10.1093/annonc/mdy126.
3
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.纳武利尤单抗联合伊匹单抗治疗高肿瘤突变负荷肺癌。
N Engl J Med. 2018 May 31;378(22):2093-2104. doi: 10.1056/NEJMoa1801946. Epub 2018 Apr 16.
4
Cytology Smears in the Era of Molecular Biomarkers in Non-Small Cell Lung Cancer: Doing More With Less.非小细胞肺癌分子生物标志物时代的细胞学涂片：用更少的资源做更多的事。
Arch Pathol Lab Med. 2018 Mar;142(3):291-298. doi: 10.5858/arpa.2017-0208-RA.
5
Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.利用 22C3 抗程序性死亡配体 1 抗体检测非小细胞肺癌患者细胞学样本中的程序性死亡配体 1 表达。
Cancer Cytopathol. 2018 Apr;126(4):264-274. doi: 10.1002/cncy.21977. Epub 2018 Feb 7.
6
Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas.肺癌中程序性死亡配体 1 免疫组化的细胞-组织学相关性。
Cancer Cytopathol. 2018 Apr;126(4):253-263. doi: 10.1002/cncy.21973. Epub 2018 Feb 5.
7
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.美国病理学家学会、国际肺癌研究协会和分子病理学会更新的肺癌患者靶向酪氨酸激酶抑制剂治疗选择的分子检测指南。
J Thorac Oncol. 2018 Mar;13(3):323-358. doi: 10.1016/j.jtho.2017.12.001. Epub 2018 Jan 25.
8
PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.非小细胞肺癌中程序性死亡受体配体1（PD-L1）的表达：细胞学、小活检及手术切除标本的比较
Cancer Cytopathol. 2017 Dec;125(12):896-907. doi: 10.1002/cncy.21937. Epub 2017 Oct 12.
9
Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx.使用PD-L1 IHC 28-8 pharmDx和PD-L1 IHC 22C3 pharmDx评估的肺癌恶性肿瘤细胞学和组织学标本中PD-L1表达的配对比较
Appl Immunohistochem Mol Morphol. 2017 Aug;25(7):453-459. doi: 10.1097/PAI.0000000000000540.
10
Preanalytic Variables in Cytology: Lessons Learned From Next-Generation Sequencing-The MD Anderson Experience.细胞学中的分析前变量：从下一代测序中吸取的经验——MD安德森癌症中心的经验
Arch Pathol Lab Med. 2016 Nov;140(11):1191-1199. doi: 10.5858/arpa.2016-0117-RA. Epub 2016 Jun 22.
Zotero 插件